The Food and Drug Administration said late Tuesday it would not approve any generic versions of OxyContin based on the original formulation because it "poses an increased potential for certain types ...
In January 2022, the Food and Drug Administration (FDA) issued a warning related to dental problems caused by buprenorphine when administered by dissolving in the mouth. This warning follows reports ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果